independently selected from the group consisting of halo, cyano, NR^7R^8, (C=O)-NR^7R^8, morpholinyl, C_{1-4}acyl, C_{1-4}alkylsulfonyl, C_{1-4}alkylsulfinyl, cycloC_{3-7}alkyl, cycloC_{3-7}alkyloxy, tetrahydropyranyloxy, tetrahydrofuranyloxy, C_{1-4}alkyloxy optionally substituted with one or more substituents each independently selected from the group consisting of halo, hydroxyl, C_{1-4}alkyloxy, and cyclopropyl, and C_{1-4}alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, hydroxyl and C_{1-4}alkyloxy optionally substituted with one or more halo substituents;

or Ar^2 is a 5- or 6-membered heteroaryl selected from the group consisting of furanyl, thiophenyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, and pyrazinyl, wherein said 5- or 6-membered heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halo, C_{1-4}alkyloxy, cyano, NR^7R^8, morpholinyl, and C_{1-4}alkyl optionally substituted with one or more halo substituents;

or Ar^2 is quinolinyl;

L^a, L^b and L^c represent a direct bond; C_{2-6}alkenediyl; carbonyl; O; S; $S(=O)_p$; NR^9; NR^9-C_{1-4}alkanediyl; C_{1-4}alkanediyl-NR^9; NR^{12}-(C=O); (C=O)-NR^{12}; or C_{1-6}alkanediyl optionally substituted with one or more substituents each independently selected from the group consisting of halo and hydroxy; two geminal hydrogen atoms in said C_{1-6}alkanediyl may be replaced by C_{1-6}alkanediyl;

p represents 1 or 2;

~~or L^a-R^{5a} and R^{4a}; or L^e-R^{5e} and R^{4e}; can be taken together to form a bivalent radical L^a-R^{5a}-R^{4a} or L^e-R^{5e}-R^{4e}, having formula~~

~~$-(CH_2)_{m-n}-Y-(CH_2)_n-$~~	~~(d-1);~~	~~$-CH=CH-N=CH-$~~	~~(d-6);~~
~~$-(CH_2)_n-Y-(CH_2)_{m-n}-$~~	~~(d-2);~~	~~$-CH=N-CH=CH-$~~	~~(d-7);~~
~~1,2-benzenediyl-$(CH_2)_r-Y-(CH_2)_{q-r}-$~~	~~(d-3);~~	~~$-N=CH-CH=CH-$~~	~~(d-8); or~~
~~1,2-benzenediyl-$(CH_2)_{q-r}-Y-(CH_2)_r-$~~	~~(d-4);~~	~~$-CH=CH-CH=N-$~~	~~(d-9);~~
~~$-CH=CH-CH=CH-$~~	~~(d-5);~~		

~~wherein (d-1), (d-2), (d-3) or (d-4) may be substituted on one or more CH_2 groups with one or two substituents each independently selected from the group consisting of hydroxyl, cyano, Ar^3, C_{1-4}acyl, and C_{1-4}alkyl optionally substituted with one or more substituents selected from the group consisting of halo and hydroxyl;~~

~~wherein two geminal hydrogen atoms in (d-1) or (d-2) may be replaced by C_{2-6}alkanediyl;~~

~~wherein (d-3) or (d-4) may be substituted on the 1,2-benzenediyl-moiety with one or more substituents each independently selected from the group consisting of halo, C_{1-4}alkyloxy, cyano, NR^7R^8, morpholinyl, and C_{1-4}alkyl optionally substituted with one or more halo substituents;~~

~~wherein (d-5), (d-6), (d-7), (d-8) or (d-9) may be substituted where possible with one or more substituents each independently selected from the group consisting of Ar^3, (C=O)-Ar^3, O-Ar^3, NR^{11}-Ar^3, C_{1-4}acyl, and C_{1-4}alkyl optionally substituted with one or more halo substituents;~~

~~Y represents a direct bond, NR^{10} or O; wherein R^{10} is hydrogen, Ar^3, C_{1-4}acyl, or C_{1-4}alkyl optionally substituted with one or more halo substituents;~~

~~m represents 3, 4, 5, 6 or 7;~~

~~n represents 0, 1, 2 or 3;~~

~~q represents 3, 4, 5 or 6;~~

~~r represents 0, 1, 2 or 3;~~

~~each Ar^3 independently represents phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, cyano, NR^7R^8, morpholinyl, cycloC_{3-7}alkyl, C_{1-4}alkyloxy optionally substituted with one or more halo substituents, and C_{1-4}alkyl optionally substituted with one or more halo substituents;~~

~~or a 5- or 6-membered heteroaryl selected from the group consisting of furanyl, thiophenyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, and pyrazinyl, wherein said 5- or 6-membered heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halo, C_{1-4}alkyloxy, cyano, NR^7R^8, morpholinyl, and C_{1-4}alkyl optionally substituted with one or more halo substituents;~~

~~or 1,6-dihydro-1-methyl-6-oxo-3-pyridinyl or 1,2-dihydro-1-methyl-2-oxo-3-pyridinyl;~~

R^{6b} and R^{6c} represent hydrogen or methyl;

each R^7 independently is hydrogen, C_{1-4}acyl, or C_{1-4}alkyl;

each R^8 independently is hydrogen or C_{1-4}alkyl;

R^9 is hydrogen, C_{1-4}acyl, or C_{1-4}alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo and cycloC_{3-7}alkyl;

~~R^{11} is hydrogen or C_{1-4}alkyl;~~

R^{12} is hydrogen or methyl;

or a pharmaceutically acceptable addition salt or a solvate thereof;

provided that the compound is not 2-[4-(1*H*-imidazol-1-yl)phenyl]-4-(trifluoromethyl)-1*H*-Imidazole.

2. The compound according to claim 1 or a stereoisomeric form thereof, wherein

~~R^1 is hydrogen or C_{1-4}alkyl;~~

~~R^2 is hydrogen or C_{1-4}alkyl;~~

~~X is CH or N;~~

A^1 is CR^{3a} or N; wherein R^{3a} is hydrogen; halo; or C_{1-4}alkyloxy;

A^2 is CR^{3b} or N; wherein R^{3b} is hydrogen or C_{1-4}alkyloxy;

A^3 and A^4 each independently are CH or N;

provided that no more than two of A^1, A^2, A^3 and A^4 are N;

~~Het^1 is a heterocycle, having formula (a), (b) or (c)~~



(a) (b) (c)

R^{4a} is hydrogen; tetrahydropyranyl; tetrahydrofuranyl; piperidinyl; morpholinyl; pyrrolidinyl; cycloC_{3-7}alkyl; Ar^1; or C_{1-6}alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, Ar^1, tetrahydropyranyl, tetrahydrofuranyl, piperidinyl, morpholinyl, pyrrolidinyl, cycloC_{3-7}alkyl, C_{1-6}alkyloxy, C_{1-6}alkylthio, and O-Ar^1;

R^{4c} is hydrogen; tetrahydropyranyl; tetrahydrofuranyl; piperidinyl; morpholinyl; pyrrolidinyl; cycloC_{3-7}alkyl; C_{1-6}alkyloxy; C_{1-6}alkylthio; Ar^1; or C_{1-6}alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, Ar^1, tetrahydropyranyl, tetrahydrofuranyl, piperidinyl, morpholinyl, pyrrolidinyl, cycloC_{3-7}alkyl, C_{1-6}alkyloxy, C_{1-6}alkylthio, and O-Ar^1;

wherein in the definitions of R^{4a} and R^{4c} piperidinyl, morpholinyl and pyrrolidinyl may be substituted with one or more substituents each independently selected from the group consisting of C_{1-4}alkyl, C_{2-6}alkenyl, C_{1-4}acyl, halo and C_{1-4}alkyloxycarbonyl;

wherein in the definitions of R^{4a} and R^{4c} each Ar^1 independently is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C_{1-4}alkyloxy, cyano, NR^7R^8, morpholinyl, and C_{1-4}alkyl

p represents 1 or 2;

or L^a-R^{5a} and R^{4a}; or L^e-R^{5e} and R^{4e}; can be taken together to form a bivalent radical L^a-R^{5a}-R^{4a} or L^e-R^{5e}-R^{4e}, having formula

$-(CH_2)_{m-n}-Y-(CH_2)_n-$ (d-1); $-1,2\text{-benzenediyl}-(CH_2)_r-Y-(CH_2)_{q-r}-$ (d-3); or

$-(CH_2)_n-Y-(CH_2)_{m-n}-$ (d-2); $-1,2\text{-benzenediyl}-(CH_2)_{q-r}-Y-(CH_2)_r-$ (d-4);

wherein (d-1), (d-2), (d-3) or (d-4) may be substituted on a CH_2 group with one or two substituents each independently selected from the group consisting of Ar^3, C_{1-4}acyl, and C_{1-4}alkyl optionally substituted with one or more halo substituents;

wherein (d-3) or (d-4) may be substituted on the 1,2-benzenediyl moiety with one or more substituents each independently selected from the group consisting of halo, C_{1-4}alkyloxy, cyano, NR^7R^8, morpholinyl, and C_{1-4}alkyl optionally substituted with one or more halo substituents;

Y represents a direct bond, NR^{10} or O; wherein R^{10} is hydrogen, Ar^3, C_{1-4}acyl, or C_{1-4}alkyl optionally substituted with one or more halo substituents;

m represents 3, 4, 5, 6 or 7;

n represents 0, 1, 2 or 3;

q represents 3, 4, 5 or 6;

r represents 0, 1, 2 or 3;

each Ar^3 independently represents phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C_{1-4}alkyloxy, cyano, NR^7R^8, morpholinyl, and C_{1-4}alkyl optionally substituted with one or more halo substituents;

or a 5- or 6-membered heteroaryl selected from the group consisting of furanyl, thiophenyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, and pyrazinyl, wherein said 5- or 6-membered heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halo, C_{1-4}alkyloxy, cyano, NR^7R^8, morpholinyl, and C_{1-4}alkyl optionally substituted with one or more halo substituents;

or 1,6-dihydro-1-methyl-6-oxo-3-pyridinyl or 1,2-dihydro-1-methyl-2-oxo-3-pyridinyl;

R^{6b} and R^{6e} represent hydrogen or methyl;

each R^7 independently is hydrogen or C_{1-4}alkyl;

each R^8 independently is hydrogen or C_{1-4}alkyl;

R^9 is hydrogen or C_{1-4}alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo and cycloC_{3-7}alkyl;

or a pharmaceutically acceptable addition salt or a solvate thereof;.

provided that the compound is not 2-[4-(1*H*-imidazol-1-yl)phenyl]-4-(trifluoromethyl)-1*H*-imidazole.

3. The compound according to claim 1 or a stereoisomeric form thereof, wherein

R^1 is hydrogen or C_{1-4}alkyl;

R^2 is hydrogen or C_{1-4}alkyl;

X is CH or N;

A^1 is CR^{3a} or N; wherein R^{3a} is hydrogen; halo; cyano; C_{1-4}alkyl; or C_{1-4}alkyloxy optionally substituted with one or more halo substituents;

A^2 is CR^{3b} or N; wherein R^{3b} is hydrogen ; fluoro; or C_{1-4}alkyloxy;

A^3 and A^4 each independently are CH; CF; or N;

provided that no more than two of A^1, A^2, A^3 and A^4 are N;

Het^1 is a heterocycle, having formula (a), (b) or (c);

R^{4a} is hydrogen; tetrahydropyranyl; tetrahydrofuranyl; piperidinyl; morpholinyl; pyrrolidinyl; cycloC_{3-7}alkyl; Ar^1; or C_{1-6}alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, hydroxyl, cyano, Ar^1, tetrahydropyranyl, tetrahydrofuranyl, piperidinyl, morpholinyl, pyrrolidinyl, cycloC_{3-7}alkyl, C_{1-6}alkyloxy, C_{1-6}alkylthio, and O-Ar^1;

R^{4e} is hydrogen; tetrahydropyranyl; tetrahydrofuranyl; piperidinyl; morpholinyl; pyrrolidinyl; cycloC_{3-7}alkyl; C_{1-6}alkyloxy; C_{1-6}alkylthio; Ar^1; or C_{1-6}alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, Ar^1, tetrahydropyranyl, tetrahydrofuranyl, piperidinyl, morpholinyl, pyrrolidinyl, cycloC_{3-7}alkyl, C_{1-6}alkyloxy, C_{1-6}alkylthio, and O-Ar^1;

wherein in the definitions of R^{4a} and R^{4e} piperidinyl, morpholinyl and pyrrolidinyl may be substituted with one or more substituents each independently selected from the group consisting of C_{2-6}alkenyl, C_{1-4}acyl, halo, C_{1-4}alkyloxycarbonyl, and C_{1-4}alkyl optionally substituted with one or more halo substituents;

wherein in the definitions of R^{4a} and R^{4e} each Ar^1 independently is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C_{1-4}alkyloxy, cyano, NR^7R^8, morpholinyl, and C_{1-4}alkyl optionally substituted with one or more halo substituents; or each Ar^1 independently is a 5- or 6-membered heteroaryl selected from the group consisting of furanyl, thiophenyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, and pyrazinyl, wherein said 5- or 6-membered heteroaryl is optionally substituted with one or more substituents each independently selected from the group

consisting of halo, C_{1-4}alkyloxy, cyano, NR^7R^8, morpholinyl, and C_{1-4}alkyl optionally substituted with one or more halo substituents;

wherein in the definitions of R^{4a} and R^{4e} each cycloC_{3-7}alkyl, tetrahydropyranyl or tetrahydrofuranyl may be substituted with one or more substituents each independently selected from the group consisting of halo, C_{1-4}alkyloxy, cyano, and C_{1-4}alkyl optionally substituted with one or more halo substituents;

R^{5a}, R^{5b} and R^{5e} are hydrogen; tetrahydropyranyl; tetrahydrofuranyl; piperidinyl; morpholinyl; pyrrolidinyl; piperazinyl; hexahydro-1*H*-1,4-diazepin-1-yl; 1,2,3,4-tetrahydro-2-quinolinyl; 3,4-dihydro-2(1*H*)-isoquinolinyl; 3,4-dihydro-1(2*H*)-quinolinyl; 2,2-difluoro-1,3-benzodioxol-5-yl; 2,2-difluoro-1,3-benzodioxol-4-yl; 1,6-dihydro-1-methyl-6-oxo-3-pyridinyl; 1,2-dihydro-1-methyl-2-oxo-3-pyridinyl; 2,3-dihydro-4*H*-1,4-benzoxazin-4-yl; 3,4-dihydro-1,5-benzoxazepin-5(2*H*)-yl; cycloC_{3-7}alkyl; Ar^2; or C_{1-6}alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo,

C_{1-4}alkyloxy, C_{1-4}acyl, and C_{1-4}alkyloxycarbonyl;

wherein in the definitions of R^{5a}, R^{5b} and R^{5e} tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, morpholinyl, pyrrolidinyl, piperazinyl, hexahydro-1*H*-1,4-diazepin-1-yl, 1,2,3,4-tetrahydro-2-quinolinyl, 3,4-dihydro-2(1*H*)-isoquinolinyl, 3,4-dihydro-1(2*H*)-quinolinyl and cycloC_{3-7}alkyl may be substituted with one or more substituents each independently selected from the group consisting of C_{2-6}alkenyl, C_{1-4}acyl, halo, C_{1-4}alkyloxycarbonyl, C_{1-4}alkyl optionally substituted with one or more halo substituents, and phenyl optionally substituted with one or more substituents each independently selected from the group consisting of C_{1-4}alkyl and trifluoromethyl;

wherein in the definitions of R^{5a}, R^{5b} and R^{5e};

Ar^2 is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, cyano, NR^7R^8, $(C=O)NR^7R^8$, morpholinyl, C_{1-4}acyl, C_{1-4}alkylsulfonyl, C_{1-4}alkylsulfinyl, cycloC_{3-7}alkyl, cycloC_{3-7}alkyloxy, tetrahydropyranyloxy, tetrahydrofuranyloxy, C_{1-4}alkyloxy optionally substituted with one or more substituents each independently selected from the group consisting of halo, hydroxyl, C_{1-4}alkyloxy, and cyclopropyl, and C_{1-4}alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, hydroxyl and C_{1-4}alkyloxy optionally substituted with one or more halo substituents;

or Ar^2 is a 5- or 6-membered heteroaryl selected from the group consisting of furanyl, thiophenyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl,

thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, and pyrazinyl, wherein said 5- or 6-membered heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halo, C_{1-4}alkyloxy, cyano, NR^7R^8, morpholinyl, and C_{1-4}alkyl optionally substituted with one or more halo substituents; or Ar^2 is quinolinyl;

L^a, L^b and L^c represent a direct bond; C_{2-6}alkenediyl; carbonyl; O; S; $S(=O)_p$; NR^9; NR^9-C_{1-4}alkanediyl; C_{1-4}alkanediyl-NR^9; NR^{12}-(C=O); (C=O)-NR^{12}; or C_{1-6}alkanediyl optionally substituted with one or more substituents each independently selected from the group consisting of halo and hydroxy; two geminal hydrogen atoms in said C_{1-6}alkanediyl may be replaced by C_{1-6}alkanediyl;

p represents 1 or 2;

R^{6b} and R^{6c} represent hydrogen or methyl;

each R^7 independently is hydrogen, C_{1-4}acyl, or C_{1-4}alkyl;

each R^8 independently is hydrogen or C_{1-4}alkyl;

R^9 is hydrogen, C_{1-4}acyl, or C_{1-4}alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo and cycloC_{3-7}alkyl;

R^{12} is hydrogen or methyl;

or a pharmaceutically acceptable addition salt or a solvate thereof;

provided that the compound is not 2-[4-(1*H*-imidazol-1-yl)phenyl]-4-(trifluoromethyl)-1*H*-Imidazole.

4. The compound according to claim 1 or a stereoisomeric form thereof, wherein

R^1 is hydrogen or C_{1-4}alkyl;

R^2 is hydrogen or C_{1-4}alkyl;

X is CH or N;

A^1 is CR^{3a} or N; wherein R^{3a} is hydrogen; halo; cyano; C_{1-4}alkyl; or C_{1-4}alkyloxy optionally substituted with one or more halo substituents;

A^2 is CR^{3b} or N; wherein R^{3b} is hydrogen ; fluoro; or C_{1-4}alkyloxy;

A^3 and A^4 each independently are CH; CF; or N;

provided that no more than two of A^1, A^2, A^3 and A^4 are N;

Het^1 is a heterocycle, having formula (a) or (c);

L^a-R^{5a} and R^{4a}; or L^c-R^{5c} and R^{4c}; are taken together to form a bivalent radical L^a-R^{5a}-R^{4a}- or L^c-R^{5c}-R^{4c}-, having formula

$-(CH_2)_{m-n}$-Y-$(CH_2)_n$- (d-1); -CH=CH-N=CH- (d-6);

-$(CH_2)_n$-Y-$(CH_2)_{m-n}$- (d-2); -CH=N-CH=CH- (d-7);
-1,2-benzenediyl-$(CH_2)_r$-Y-$(CH_2)_{q-r}$- (d-3); -N=CH-CH=CH- (d-8); or
-1,2-benzenediyl-$(CH_2)_{q-r}$-Y-$(CH_2)_r$- (d-4); -CH=CH-CH=N- (d-9);
-CH=CH-CH=CH- (d-5);

wherein (d-1), (d-2), (d-3) or (d-4) may be substituted on one or more CH_2 groups with one or two substituents each independently selected from the group consisting of hydroxyl, cyano, Ar^3, C_{1-4}acyl, and C_{1-4}alkyl optionally substituted with one or more substituents selected from the group consisting of halo and hydroxyl;

wherein two geminal hydrogen atoms in (d-1) or (d-2) may be replaced by C_{2-6}alkanediyl;

wherein (d-3) or (d-4) may be substituted on the 1,2-benzenediyl moiety with one or more substituents each independently selected from the group consisting of halo, C_{1-4}alkyloxy, cyano, NR^7R^8, morpholinyl, and C_{1-4}alkyl optionally substituted with one or more halo substituents;

wherein (d-5), (d-6), (d-7), (d-8) or (d-9) may be substituted where possible with one or more substituents each independently selected from the group consisting of Ar^3, (C=O)-Ar^3, O-Ar^3, NR^{11}-Ar^3, C_{1-4}acyl, and C_{1-4}alkyl optionally substituted with one or more halo substituents;

Y represents a direct bond, NR^{10} or O; wherein R^{10} is hydrogen, Ar^3, C_{1-4}acyl, or C_{1-4}alkyl optionally substituted with one or more halo substituents;

m represents 3, 4, 5, 6 or 7;

n represents 0, 1, 2 or 3;

q represents 3, 4, 5 or 6;

r represents 0, 1, 2 or 3;

each Ar^3 independently represents phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, cyano, NR^7R^8, morpholinyl, cycloC_{3-7}alkyl, C_{1-4}alkyloxy optionally substituted with one or more halo substituents, and C_{1-4}alkyl optionally substituted with one or more halo substituents;

or a 5- or 6-membered heteroaryl selected from the group consisting of furanyl, thiophenyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, and pyrazinyl, wherein said 5- or 6-membered heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halo, C_{1-4}alkyloxy, cyano, NR^7R^8, morpholinyl, and C_{1-4}alkyl optionally substituted with one or more halo substituents;

~~or 1,6-dihydro-1-methyl-6-oxo-3-pyridinyl or 1,2-dihydro-1-methyl-2-oxo-3-pyridinyl;~~

~~R^{6b} and R^{6c} represent hydrogen or methyl;~~

~~each R^7 independently is hydrogen, C_{1-4}acyl, or C_{1-4}alkyl;~~

~~each R^8 independently is hydrogen or C_{1-4}alkyl;~~

~~R^{11} is hydrogen or C_{1-4}alkyl;~~

~~or a pharmaceutically acceptable addition salt or a solvate thereof.~~

~~53~~. The compound according to claim 1 or a stereoisomeric form thereof, wherein

~~R^1 is hydrogen or C_{1-4}alkyl;~~

~~R^2 is hydrogen or C_{1-4}alkyl;~~

~~X is CH or N;~~

A^1 is CR^{3a} or N; wherein R^{3a} is hydrogen; cyano; C_{1-4}alkyl; or C_{1-4}alkyloxy optionally substituted with one or more halo substituents;

A^2 is CR^{3b} or N; wherein R^{3b} is hydrogen ; fluoro; or C_{1-4}alkyloxy;

A^3 is CH or CF;

A^4 is CH;

provided that when A^1 is N, then A^2 is CR^{3b}, and when A^2 is N, then A^1 is CR^{3a};

~~Het^1 is a heterocycle, having formula (a), (b) or (c)~~

R^{4a} is hydrogen; cycloC_{3-7}alkyl; Ar^1; or C_{1-6}alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, hydroxyl, cyano, Ar^1, cycloC_{3-7}alkyl, C_{1-6}alkyloxy;

R^{4c} is Ar^1 or C_{1-6}alkyl;

wherein in the definitions of R^{4a} and R^{4c} each Ar^1 independently is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo and C_{1-4}alkyl optionally substituted with one or more halo substituents;

R^{5a}, R^{5b} and R^{5c} are hydrogen; piperidinyl; morpholinyl; pyrrolidinyl; hexahydro-1*H*-1,4-diazepin-1-yl; 1,2,3,4-tetrahydro-2-quinolinyl; 3,4-dihydro-2(1*H*)-isoquinolinyl; 3,4-dihydro-1(2*H*)-quinolinyl; 2,2-difluoro-1,3-benzodioxol-5-yl; 2,2-difluoro-1,3-benzodioxol-4-yl; 2,2-difluoro-1,3-benzodioxol-4-yl; 1,6-dihydro-1-methyl-6-oxo-3-pyridinyl; 1,2-dihydro-1-methyl-2-oxo-3-pyridinyl; 2,3-dihydro-4*H*-1,4-benzoxazin-4-yl; 3,4-dihydro-1,5-benzoxazepin-5(2*H*)-yl; cycloC_{3-7}alkyl; Ar^2; or C_{1-6}alkyl;

wherein in the definitions of R^{5a}, R^{5b} and R^{5c} piperidinyl, morpholinyl, pyrrolidinyl, hexahydro-1*H*-1,4-diazepin-1-yl, and cycloC_{3-7}alkyl may be substituted with one or more substituents each independently selected from the group consisting of

C_{1-4}acyl, C_{1-4}alkyl optionally substituted with one or more halo substituents, and phenyl optionally substituted with one or more trifluoromethyl groups;

wherein in the definitions of R^{5a}, R^{5b} and R^{5c},

Ar^2 is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, cyano, NR^7R^8, $(C=O)$-NR^7R^8, C_{1-4}acyl, C_{1-4}alkylsulfonyl, C_{1-4}alkylsulfinyl, tetrahydrofuranyloxy, C_{1-4}alkyloxy optionally substituted with one or more substituents each independently selected from the group consisting of halo, C_{1-4}alkyloxy, and cyclopropyl, and C_{1-4}alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, hydroxyl and C_{1-4}alkyloxy;

or Ar^2 is a 5- or 6-membered heteroaryl selected from the group consisting of pyridinyl and pyrazolyl, wherein said 5- or 6-membered heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halo, C_{1-4}alkyloxy, and C_{1-4}alkyl optionally substituted with one or more halo substituents;

or Ar^2 is quinolinyl;

L^a, L^b and L^c represent a direct bond; C_{2-6}alkenediyl; carbonyl; O; S; NR^9; NR^9-C_{1-4}alkanediyl; C_{1-4}alkanediyl-NR^9; $(C=O)$-NR^{12}; or C_{1-6}alkanediyl optionally substituted with one or more substituents each independently selected from the group consisting of halo and hydroxy; two geminal hydrogen atoms in said C_{1-6}alkanediyl may be replaced by C_{1-6}alkanediyl;

~~or L^a-R^{5a} and R^{4a}; or L^e-R^{5e} and R^{4e}; can be taken together to form a bivalent radical L^a-R^{5a}-R^{4a} or L^e-R^{5e}-R^{4e}-, having formula~~

~~$-(CH_2)_{m-n}$-Y-$(CH_2)_n$-~~	~~(d-1);~~	~~-CH=CH-CH=CH-~~	~~(d-5);~~
~~$-(CH_2)_n$-Y-$(CH_2)_{m-n}$-~~	~~(d-2);~~	~~-CH=N-CH=CH-~~	~~(d-7); or~~
~~-1,2-benzenediyl-$(CH_2)_r$-Y-$(CH_2)_{q-r}$-~~	~~(d-3);~~	~~-N=CH-CH=CH-~~	~~(d-8);~~

~~wherein (d-1) or (d-2) may be substituted on one CH_2 group with an Ar^3 substituent and optionally (d-1) or (d-2) is substituted on the same or a different CH_2 group with one substituent selected from the group consisting of hydroxyl and C_{1-4}alkyl optionally substituted with one or more hydroxyl substituents; wherein two geminal hydrogen atoms in (d-1) or (d-2) may be replaced by 1,5-pentanediyl;~~

~~wherein (d-5), (d-7) or (d-8) is substituted where possible with one substituent selected from the group consisting of Ar^3 and NR^{11}-Ar^3;~~

~~Y represents a direct bond, NR^{10} or O; wherein R^{10} is hydrogen, Ar^3, C_{1-4}acyl, or C_{1-4}alkyl;~~

~~m represents 3, 4, 5 or 6;~~

~~n represents 0, 1 or 2;~~

~~q represents 3, 4, 5 or 6;~~

~~r represents 3;~~

~~each Ar^3 independently represents phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, cycloC_{3-7}alkyl, C_{1-4}alkyloxy optionally substituted with one or more halo substituents, and C_{1-4}alkyl optionally substituted with one or more halo substituents;~~

~~R^{6b} and R^{6c} represent hydrogen or methyl;~~

each R^7 independently is C_{1-4}acyl or C_{1-4}alkyl;

~~each R^8 independently is hydrogen or C_{1-4}alkyl;~~

R^9 is hydrogen, C_{1-4}acyl, or C_{1-4}alkyl;

~~R^{11} is hydrogen;~~

R^{12} is hydrogen;

or a pharmaceutically acceptable addition salt or a solvate thereof.

~~6. The compound according to claim 1, wherein~~

~~L^a, L^b and L^c represent NH;~~

~~or $-L^a-R^{5a}$ and R^{4a}; or $-L^c-R^{5c}$ and R^{4c}; can be taken together to form a bivalent radical as defined in claim 1.~~

~~7~~4. The compound according to claim 1, wherein

A^1 represents C-O-CH_3;

A^2 represents CH or N.

5. The compound according to claim 1, wherein Het^1 is an heterocycle having formula (a) or (b).

~~8~~6. The compound according to claim 1, wherein

Het^1 is an heterocycle having formula (a).

~~9~~7. The compound according to claim ~~3~~1, wherein

R^1 is C_{1-4}alkyl;

R^2 is hydrogen;

X is CH;

A^1 is CR^{3a}; wherein R^{3a} is C_{1-4}alkyloxy;

A^2 is CH or N;

A^3 and A^4 are CH;

Het^1 is a heterocycle having formula (a); wherein

R^{4a} is C_{1-6}alkyl;

R^{5a} is phenyl substituted with one, two or three substituents each independently selected from the group consisting of halo, C_{1-4}alkyl optionally substituted with one or more halo substituents, and C_{1-4}alkyloxy optionally substituted with one or more halo substituents;

L^a represents NH.

~~108~~. The compound according to claim 1, wherein the compound is

N-[2-fluoro-3-methoxy-5-(trifluoromethyl)phenyl]-3-[6-methoxy-5-(4-methyl-1*H*-imidazol-1-yl)-2-pyridinyl]-1-methyl-1*H*-1,2,4-triazol-5-amine,

~~(8S)-5,6,7,8-tetrahydro-2-[6-methoxy-5-(4-methyl-1*H*-imidazol-1-yl)-2-pyridinyl]-8-[2-methyl-5-(trifluoromethyl)phenyl]-[1,2,4]triazolo[1,5-a]pyridine,~~

~~(8S)-8-[2-fluoro-5-(trifluoromethoxy)phenyl]-5,6-dihydro-2-[3-methoxy-4-(4-methyl-1*H*-imidazol-1-yl)phenyl]-8*H*-[1,2,4]triazolo[5,1-c][1,4]oxazine,~~

~~(8S)-8-(4-fluoro-2-methylphenyl)-5,6,7,8-tetrahydro-2-[3-methoxy-4-(4-methyl-1*H*-imidazol-1-yl)phenyl]-[1,2,4]triazolo[1,5-a]pyridine,~~

~~(8S)-8-(4-fluoro-2-methylphenyl)-5,6,7,8-tetrahydro-2-[3-methoxy-4-(4-methyl-1*H*-imidazol-1-yl)phenyl]-[1,2,4]triazolo[1,5-a]pyridine .HCl,~~

N-[2-fluoro-3-methoxy-5-(trifluoromethyl)phenyl]-3-[3-methoxy-4-(4-methyl-1*H*-imidazol-1-yl)phenyl]-1-methyl-1*H*-1,2,4-triazol-5-amine,

~~(8S)-5,6,7,8-tetrahydro-2-[6-methoxy-5-(4-methyl-1*H*-imidazol-1-yl)-2-pyridinyl]-8-[2-(trifluoromethyl)phenyl]-[1,2,4]triazolo[1,5-a]pyridine,~~

3-[3-methoxy-4-(4-methyl-1*H*-imidazol-1-yl)phenyl]-1-methyl-*N*-(2-methylphenyl)-1*H*-1,2,4-triazol-5-amine,

N-[3-fluoro-2-(trifluoromethyl)phenyl]-3-[6-methoxy-5-(4-methyl-1*H*-imidazol-1-yl)-2-pyridinyl]-1-methyl-1*H*-1,2,4-triazol-5-amine,

N-[2-fluoro-3-(trifluoromethyl)phenyl]-3-[6-methoxy-5-(4-methyl-1*H*-imidazol-1-yl)-2-pyridinyl]-1-methyl-1*H*-1,2,4-triazol-5-amine,

N-[2-fluoro-5-(trifluoromethoxy)phenyl]-3-[6-methoxy-5-(4-methyl-1*H*-imidazol-1-yl)-2-pyridinyl]-1-methyl-1*H*-1,2,4-triazol-5-amine,

3-[3-methoxy-4-(4-methyl-1*H*-imidazol-1-yl)phenyl]-1-methyl-*N*-[2-(trifluoromethyl)phenyl]-1*H*-1,2,4-triazol-5-amine, or

N-[2-fluoro-5-(trifluoromethyl)phenyl]-3-[6-methoxy-5-(4-methyl-1*H*-imidazol-1-yl)-2-pyridinyl]-1-methyl-1*H*-1,2,4-triazol-5-amine,

or a pharmaceutically acceptable addition salt or a solvate thereof.

~~11~~9. The compound according to claim ~~1~~8, wherein the compound is 3-[3-methoxy-4-(4-methyl-1*H*-imidazol-1-yl)phenyl]-1-methyl-*N*-(2-methylphenyl)-1*H*-1,2,4-triazol-5-amine.

10. The compound according to claim 8, wherein the compound is

N-[2-fluoro-5-(trifluoromethoxy)phenyl]-3-[6-methoxy-5-(4-methyl-1*H*-imidazol-1-yl)-2-pyridinyl]-1-methyl-1*H*-1,2,4-triazol-5-amine,

or a pharmaceutically acceptable addition salt or solvate thereof.

11. The compound according to claim 10, wherein the compound is *N*-[2-fluoro-5-(trifluoromethoxy)phenyl]-3-[6-methoxy-5-(4-methyl-1*H*-imidazol-1-yl)-2-pyridinyl]-1-methyl-1*H*-1,2,4-triazol-5-amine.

12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as defined in any one of claims 1 to 11.

13. A compound as defined in one of claims 1 to 11 for use as a medicament.

14. A compound as defined in any one of claims 1 to 11 for use in the treatment or prevention of diseases or conditions selected from the group consisting of Alzheimer's disease, traumatic brain injury, mild cognitive impairment, senility, dementia, dementia with Lewy bodies, cerebral amyloid angiopathy, multi-infarct dementia, Down's syndrome, dementia associated with Parkinson's disease and dementia associated with beta-amyloid.

15. The compound according to claim 14 wherein the compound is for use in the treatment or prevention of Alzheimer's disease.